Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
Neurosurgery ; 2024 Jan 11.
Article in English | MEDLINE | ID: mdl-38206045

ABSTRACT

Skull base surgery is a young surgical subspecialty currently led by its second generation of surgeons. At present, there is no literature that narrates the connection of the present to the past. An extended interview was held with Dr Jon H. Robertson, who helped establish the subspecialty in Memphis, TN, to aid in identifying and connecting sentinel events and key figures in the development of the discipline. The field drastically evolved during his era of practice (1975-present), with the advent of advanced imaging and technology, as well as the emergence of multidisciplinary skull base surgical teams. The intersection of the careers of Jon H. Robertson, James T. Robertson, Gale Gardner, Edwin Cocke, John Shea, Jr., and Jerrall Crook in Memphis catalyzed the standardization of a multidisciplinary approach to cranial base pathology. We report the findings of Dr Jon H. Robertson's extended interview, told against the backdrop of the history of the subspecialty. The story of the development of skull base surgery is told from the unique perspective of one who lived and shaped a pivotal segment in this historical timeline.

2.
Cureus ; 13(11): e19638, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34956763

ABSTRACT

Introduction Lesions of the jugular foramen (JF) and postero-lateral skull base are difficult to expose and exhibit complex neurovascular relationships. Given their rarity and the increasing use of radiosurgery, neurosurgeons are becoming less experienced with their surgical management. Anatomical factors are crucial in designing the approach to achieve a maximal safe resection. Methods and methods Six cadaveric heads (12 sides) were dissected via combined post-auricular infralabyrinthine and distal transcervical approach with additional anterior transstyloid and posterior far lateral exposures. Contiguous surgical triangles were measured, and contents were analyzed. Thirty-one patients (32 lesions) were treated surgically between 2000 and 2016 through different variations of the retro-auricular distal cervical transtemporal approaches. Results We anatomically reviewed the carotid, stylodigastric, jugular, condylar, suboccipital, deep condylar, mastoid, suprajugular, suprahypoglossal (infrajugular), and infrahypoglossal triangles. Tumors included glomus jugulare, lower cranial nerve schwannomas or neurofibromas, meningiomas, chondrosarcoma, adenocystic carcinoma, plasmacytoma of the occipitocervical joint, and a sarcoid lesion. We classified tumors into extracranial, intradural, intraosseous, and dumbbell-shaped, and analyzed the approach selection for each. Conclusion Jugular foramen and posterolateral skull base lesions can be safely resected through a retro-auricular distal cervical lateral skull base approach, which is customizable to anatomical location and tumor extension by tailoring the involved osteo-muscular triangles.

3.
J Neurosurg ; : 1-8, 2020 Aug 07.
Article in English | MEDLINE | ID: mdl-32764183

ABSTRACT

OBJECTIVE: The Neurosurgery Research & Education Foundation (NREF), previously known as the Research Foundation of the American Association of Neurological Surgeons (AANS), was established in 1980 to encourage and facilitate innovation through financial support to young neurosurgeons in the process of honing their competencies in neurosciences and neurological surgery. This article provides a historical overview of NREF, its mission, and charitable contributions and the ever-expanding avenues for neurosurgeons, neurosurgical residents and fellows, and medical students to supplement clinical training and to further neurosurgical research advances. METHODS: Data were collected from the historical archives of the AANS and NREF website. Available data included tabulated revenue, geographic and institutional records of funding, changes in funding for fellowships and awards, advertising methods, and sources of funding. RESULTS: Since 1984, NREF has invested more than $23 million into the future of neurosurgery. To date, NREF has provided more than 500 fellowship opportunities which have funded neurosurgeons' education and research efforts at all stages of training and practice. CONCLUSIONS: NREF is designed to serve as the vehicle through which the neurosurgical community fosters the continued excellence in the care of patients with neurosurgical diseases.

4.
J Neurol Surg B Skull Base ; 80(5): 518-526, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31534895

ABSTRACT

Introduction The jugular foramen occupies a complex and deep location between the skull base and the distal-lateral-cervical region. We propose a morphometric anatomical model to deconstruct its surgical anatomy and offer various quantifiable target-guided exposures and angles-of-attack. Methods Six cadaveric heads (12 sides) were dissected using a combined postauricular infralabyrinthine and distal transcervical approach with additional anterior transstyloid and posterior far lateral exposures. We identified anatomical landmarks and combined new and previously described contiguous triangles to expose the region; we defined the jugular and deep condylar triangles. Angles-of-attack to the jugular foramen were measured after removing the digastric muscle, styloid process, rectus capitis lateralis, and occipital condyle. Results Removing the digastric muscle and styloid process allowed 86.4° laterally and 85.5° anteriorly, respectively. Resecting the rectus capitis lateralis and jugular process provided the largest angle-of-attack (108.4° posteriorly). The occipital condyle can be drilled in the deep condylar triangle only adding 30.4° medially. A purely lateral approach provided a total of 280.3°. Cutting the jugular ring and mobilizing the vein can further expand the medial exposure. Conclusion The microsurgical anatomy of the jugular foramen can be deconstructed using a morphometric model, permitting a surgical approach customized to the pathology of interest.

5.
J Neurol Surg B Skull Base ; 78(3): 251-255, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28593112

ABSTRACT

Objective This case series investigates management of glomus jugulare (GJ) tumors utilizing definitive and salvage Gamma Knife stereotactic radiosurgery (GKSRS). Methods A retrospective chart review was performed to collect data. Statistical analysis included patient, tumor, and treatment information. Results From 1996 to 2013, 17 patients with GJ received GKSRS. Median age was 64 years (range, 27-76). GKSRS was delivered for definitive treatment in eight (47%) and salvage in nine (53%) patients. Median tumor volume was 9.8 cm 3 (range, 2.8-42 cm 3 ). Median dose was 15 Gy (range, 13-18 Gy). Median follow-up was 123 months (range, 38-238 months). Tumor size decreased in 10 (59%), stabilized in 6 (35%), and increased in 1 patient (6%). Overall neurological deficit improved in 53%, stabilized in 41%, and worsened in 6% of patients. Overall cause-specific survival was 100%, and actuarial local control was 94%. Eighty-eight percent of patients without prior resection experienced neurologic deficit improvement, while 25% of patients with prior resection experienced neurologic improvement ( p = 0.02). Conclusion Gamma Knife radiosurgery provides effective long-term control of GJ and overall improvement or stabilization of neurological deficit in most patients. Patients with prior resection are less likely to experience improvement of neurologic deficit.

6.
J Neurol Surg B Skull Base ; 77(4): 291-3, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27478756
8.
J Neurol Surg B Skull Base ; 75(4): 236-42, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25093146

ABSTRACT

Objectives The far-lateral approach is widely used to treat pathology of the ventral foramen magnum. Numerous methods of exposure have been described, most of which utilize long skin incisions and myocutaneous flaps. Here we present our experience with gaining exposure through a small paramedian incision using a muscle-splitting technique. Design A cadaveric anatomical study was first performed to verify the feasibility of the approach. We then describe our experience with using the approach in 13 patients. A retrospective chart review was performed and data regarding pathology, imaging, and complications were collected. Results The cadaveric study confirmed that a small paramedian muscle-splitting approach allows sufficient exposure to approach many foramen magnum lesions. Our case series included 10 patients with meningioma, one brainstem glioblastoma, one posterior inferior cerebellar artery aneurysm, and one odontoid pannus. The exposure was adequate in all cases. For the meningioma patients, six had gross total resections and four had subtotal resection because of tumor adherence to neurovascular structures. Two patients experienced postoperative cardiovascular complications. There were no new neurologic deficits, cerebrospinal fluid leaks, or wound complications. Conclusions A small paramedian incision may be used to gain exposure and perform successful far-lateral approaches. The small exposure is likely to reduce the risk of local complications such as cerebrospinal fluid fistula and pseudomeningocele when compared with larger exposures.

9.
J Neurooncol ; 110(2): 163-77, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22875710

ABSTRACT

Glioblastoma multiforme (GBM) is the most common and devastating form of primary central nervous system malignancy. The prognosis for patients diagnosed with GBM is poor, having a median survival rate of 12-15 months. Despite modern advances in the development of antineoplastic agents, the efficacy of newer anti-cancer agents in the treatment of GBM is yet to be determined. Thus, there remains a significant unmet need for new therapeutic strategies against GBM. A promising chemotherapeutic intervention has emerged from studies of cannabinoid receptor agonists wherein tetrahydrocannabinol has been the most extensively studied. The novel cannabinoid ligand KM-233 was developed as a lead platform for future optimization of biopharmaceutical properties of classical based cannabinoid ligands. Treatment of U87MG human GBM cells with KM-233 caused a time dependent change in the phosphorylation profiles of MEK, ERK1/2, Akt, BAD, STAT3, and p70S6K. Almost complete mitochondrial depolarization was observed 6 h post-treatment followed by a rapid increase in cleaved caspase 3 and significant cytoskeletal contractions. Treatment with KM-233 also resulted in a redistribution of the Golgi-endoplasmic reticulum structures. Dose escalation studies in the orthotopic model using U87MG cells revealed an 80 % reduction in tumor size after 12 mg/kg daily dosing for 20 days. The evaluation of KM-233 against primary tumor tissue in the side flank model revealed a significant decrease in the rate of tumor growth. These findings indicate that structural refinement of KM-233 to improve its biopharmaceutical properties may lead to a novel and efficacious treatment for GBM.


Subject(s)
Brain Neoplasms/drug therapy , Cannabinoids/therapeutic use , Glioma/drug therapy , Animals , Apoptosis/drug effects , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Caspase 3/metabolism , Disease Models, Animal , Female , Glioma/metabolism , Glioma/pathology , Humans , Male , Membrane Potential, Mitochondrial/drug effects , Mice , Mice, Inbred BALB C , Mice, SCID , Phosphoproteins/metabolism , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/metabolism , Tumor Cells, Cultured
10.
Neurosurg Focus ; 33(Suppl 1): 1, 2012 Jul.
Article in English | MEDLINE | ID: mdl-26016398

ABSTRACT

A young man with type 1 neurofibromatosis presented with progressive myelopathy. Imaging revealed an anterolateral mass within the spinal canal at C1-2, with severe compression of the spinal cord. A far-lateral approach was used to remove the mass, which proved to be an extradural neurofibroma. This narrated stereoscopic video details the important steps of the operation. The video can be found here: http://youtu.be/td4MjLtiMbk .

12.
J Neurosurg ; 112(1): 189-98, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19522575

ABSTRACT

Neurological surgery was defined as a separate surgical specialty by Harvey Cushing and a few other surgeons, most of whom were trained and influenced by Cushing. One of these, Raphael Eustace Semmes, became the first neurosurgeon in Memphis, Tennessee, in 1912. After World War II, Semmes and his first associate, Francis Murphey, incorporated the Semmes-Murphey Clinic, which has been primarily responsible for the growth of the Department of Neurosurgery at the University of Tennessee Health Science Center in Memphis, as well as the development of select neurosurgical subspecialties in Memphis area hospitals.


Subject(s)
Academic Medical Centers/history , Neurosurgery/history , Universities/history , History, 19th Century , History, 20th Century , Humans , Intervertebral Disc Displacement/diagnosis , Intervertebral Disc Displacement/history , Intervertebral Disc Displacement/surgery , Tennessee , United States
13.
J Neurosurg ; 109(6): 979-88, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19035707

ABSTRACT

The primary purpose of the relationship between neurosurgery and industry must be to improve patient care and advance medical knowledge. This relationship is desirable and can be mutually beneficial. Strict adherence to established ethical and legal guidelines is necessary to avoid financial conflicts of interest that may occur between neurosurgery and industry. The Code of Ethics established by the American Association of Neurological Surgeons (AANS) in 1986 emphasizes the physician's responsibility to always act in the best interest of his or her patients. The AANS Guidelines for Corporate Relations were developed in 2004 to address the concern of the potential growing influence of industry in the activities of our neurosurgical organization. Recognizing a need to clarify the proper relationships between neurosurgeons and industry, Guidelines on Neurosurgeon-Industry Conflicts of Interest were recently established. The AANS is committed to the highest ethical and legal standards in future relations with our industry partners. Members of the AANS are encouraged to adhere to the voluntary guidelines established by our organization.


Subject(s)
Industry/ethics , Neurosurgery/ethics , Patient Care/trends , Conflict of Interest , Guidelines as Topic , Humans , Industry/economics , Industry/legislation & jurisprudence , Neurosurgery/economics , Neurosurgery/legislation & jurisprudence , Professional Practice , Societies, Medical
14.
Brain Res ; 1047(1): 56-64, 2005 Jun 14.
Article in English | MEDLINE | ID: mdl-15893739

ABSTRACT

The myelodysplasia/myeloid leukemia factor 1-interacting protein MLF1IP is a novel gene which encodes for a putative transcriptional repressor. It is localized to human chromosome 4q35.1 and is expressed in both the nuclei and cytoplasm of cells. Northern and Western blot analyses have revealed MLF1IP to be present at very low amounts in normal brain tissues, whereas a number of human and rat glioblastoma (GBM) cell lines demonstrated a high level expression of the MLF1IP protein. Immunohistochemical analysis of rat F98 and C6 GBM tumor models showed that MLF1IP was highly expressed in the tumor core where it was co-localized with MLF1 and nestin. Moreover, MLF1IP expression was elevated in the contralateral brain where no tumor cells were detected. These observations, together with previous data demonstrating a role for MLF1IP in erythroleukemias, suggest a possible function for this protein in glioma pathogenesis and potentially in other types of malignancies.


Subject(s)
Brain Neoplasms/metabolism , Gene Expression Regulation, Neoplastic , Glioblastoma/metabolism , Nuclear Proteins/metabolism , Animals , Brain Neoplasms/physiopathology , Cell Cycle Proteins , Cell Line, Tumor , Cell Proliferation , Cell Transformation, Neoplastic/metabolism , DNA-Binding Proteins , Disease Models, Animal , Glioblastoma/physiopathology , Histones , Humans , Immunohistochemistry , Intermediate Filament Proteins/metabolism , Nerve Tissue Proteins/metabolism , Nestin , Proteins/metabolism , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley , Up-Regulation/physiology
15.
J Neurooncol ; 72(1): 67-75, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15803378

ABSTRACT

INTRODUCTION: Malignancies of the nasal and paranasal sinuses are uncommon tumors, accounting for only 3% of all aerodigestive tract neoplasms. Despite advances in surgical techniques and continued evolution of adjuvant therapies, the 5-year mortality remains unusually high at greater than 50%. In 1996, we begin utilizing a novel strategy in the treatment of advanced sinonasal carcinomas. This consisted of neoadjuvant selective intra-arterial cisplatin with concurrent radiation therapy (acronym RADPLAT) followed by a conservative craniofacial resection. We now report our results for 11 patients treated with this regimen. METHODS: Between July 1996 and April 2003, 11 patients with advanced sinonasal malignancies underwent treatment utilizing the RADPLAT protocol followed by a planned surgical resection via a craniofacial approach. Patient charts, operative notes, follow-up clinic notes, and pre- and post-operative imaging studies were reviewed in detail for each subject. RESULTS: Histopathological analysis of the tumors revealed seven squamous cell carcinomas (64%), two adenocarcinomas (18%), one adenoid cystic carcinoma (9%), and one sinonasal undifferentiated carcinoma (9%). T4N0M0 disease was present in nine patients (81%), and two patients had T3N0M0 disease (19%). Survival was calculated using the Kaplan-Meier method with an overall survival of 81% at 5 years and a progression-free survival at 5 years of 67%. Mean follow-up is 57.2 months ranging from 12 to 95 months. CONCLUSIONS: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation results in a significant improvement in survival. This can be done safely with high response rates and excellent loco-regional control in T3 and T4 disease. Although are results are encouraging, there is a need for a cooperative, multi-institutional, prospective study.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma/drug therapy , Carcinoma/radiotherapy , Cisplatin/administration & dosage , Paranasal Sinus Neoplasms/drug therapy , Paranasal Sinus Neoplasms/radiotherapy , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Carcinoma/pathology , Carcinoma/surgery , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Female , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Neoadjuvant Therapy/methods , Paranasal Sinus Neoplasms/pathology , Paranasal Sinus Neoplasms/surgery , Premedication , Radiation-Sensitizing Agents/administration & dosage , Statistics, Nonparametric , Survival Analysis , Treatment Outcome
16.
J Neurooncol ; 71(3): 245-55, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15735912

ABSTRACT

To investigate adult neural stem cell (NSC) biology in relation to glioma, the C6 glioma cell line was tagged with green fluorescent protein (GFP) and inoculated into the brain of adult rats. The in vivo biological response of the brain to glioma was studied using immunohistochemical analysis of the subventricular zone (SVZ), peritumoral areas, and glioma. Nestin immunoreactive cells were found infiltrating glioma, but the distribution of abnormal immunoreactivity was restricted to the dorsal and medial border of the tumor relative to the ipsilateral ventricle. The SVZ was found to be hypertrophic, hypercellular, and up-regulated nestin expression. Furthermore, a dense contiguous population of nestin immunoreactive cells could be found streaming from ipsilateral dorsal tip of the SVZ, tracking along the ventral margin of the corpus callosum, and fanning out to encompass and infiltrate the proximal tumor border. Although most cells were either nestin or glial fibrillary acidic protein (GFAP) immunoreactive in the SVZ and along the ventral margin of the corpus callosum, the number of cells co-expressing both markers increased proportionally as the tumor was approached so that the predominant cell population along the proximal tumor border was GFAP immunoreactive. Finally, we demonstrated that a significant proportion of cells found in areas of abnormal immunoreactivity were proliferating, especially in peritumoral areas. In summary, there is an induction of neuropoietic activity in a rat intracranial glioma model that results in an infiltration and accumulation of abnormal nestin and GFAP expressing cells with proliferative potential along the dorsal and medial border of intracranial C6 glioma.


Subject(s)
Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Glioma/metabolism , Glioma/pathology , Neuroglia/metabolism , Neuroglia/pathology , Stem Cells/metabolism , Animals , Cell Differentiation , Cell Lineage , Cell Movement , Cerebral Ventricles/pathology , Disease Models, Animal , Fluorescent Antibody Technique , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Intermediate Filament Proteins/metabolism , Neoplasm Transplantation , Nerve Tissue Proteins/metabolism , Nestin , Rats , Rats, Inbred WF , Rats, Sprague-Dawley , Stem Cells/cytology , Up-Regulation
17.
J Neurooncol ; 70(1): 3-15, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15527101

ABSTRACT

Cadherins are Ca2+-dependent cell adhesion molecules that play an important role in tissue construction and morphogenesis in multicellular organisms. Over the last few years, reports have emerged in the literature describing the involvement of cadherins in tumor invasion and metastasis. Cadherins typically demonstrate up and down-regulation according to the biological needs of the tissue. Additionally, up-regulation of N-cadherin is thought to be important for tumor formation in early stages of tumor development. We studied N-cadherin in surgical specimens of patients with primary glioblastoma by microarray analysis and found that N-cadherin mRNA expression is up-regulated compared to normal brain. To study the effects of N-cadherin expression on invasion and metastasis in vitro and in vivo, we overexpressed N-cadherin in the rat C6 glioma cell line which normally has low levels of N-cadherin. We found that up-regulation of N-cadherin resulted in a slight decreased adhesion to type IV collagen, fibronectin, and laminin, but statistically significant decreased adhesion to type I collagen. Furthermore, increased expression of N-cadherin correlated with a dramatic decrease in invasive behavior in extracellular matrix invasion assays. We then proceeded to study these cell lines in vivo in a rat intracranial glioma model, and found that N-cadherin expression inversely correlated with invasion into surrounding tissues, irregular margins, and extracranial invasion. In summary, these data collectively demonstrate that N-cadherin levels are important in the malignant behavior of gliomas, and may serve as a prognostic indicator for patients with high-grade gliomas.


Subject(s)
Brain Neoplasms/metabolism , Cadherins/metabolism , Gene Expression Regulation, Neoplastic , Glioma/metabolism , Adult , Aged , Aged, 80 and over , Animals , Brain Neoplasms/pathology , Cadherins/genetics , Cell Adhesion , Cell Aggregation/drug effects , Collagen Type I/metabolism , Collagen Type IV/metabolism , Female , Fibronectins/metabolism , Gene Expression Profiling , Glioma/pathology , Humans , Laminin/metabolism , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Oligonucleotide Array Sequence Analysis , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Tumor Cells, Cultured
18.
Neurosurg Focus ; 17(2): E1, 2004 Aug 15.
Article in English | MEDLINE | ID: mdl-15329016

ABSTRACT

The treatment of glomus jugulare tumors presents the surgeon with a significant management problem. Because the neoplasm originates in the region of the jugular bulb, it frequently involves the lower cranial nerves, with occasional extension into the posterior fossa. Despite extensive work on the development of surgical and radiation treatment strategies, considerable controversy still exists regarding the optimal management of these lesions. A historical review of the development of management options for glomus jugulare tumors is presented in an effort to offer a foundation for understanding their contemporary treatment.


Subject(s)
Glomus Jugulare Tumor/history , Case Management , Cranial Nerve Injuries/etiology , Cranial Nerve Injuries/prevention & control , Glomus Jugulare Tumor/pathology , Glomus Jugulare Tumor/radiotherapy , Glomus Jugulare Tumor/surgery , Hearing Loss, Sensorineural/etiology , Hearing Loss, Sensorineural/prevention & control , History, 20th Century , Humans , Neoplasm Invasiveness , Palliative Care , Postoperative Complications/prevention & control , Radiation Injuries/etiology , Radiation Injuries/prevention & control , Radiosurgery/history , Radiotherapy/adverse effects , Stroke/etiology , Stroke/prevention & control
19.
J Neurosurg ; 100(6): 1049-59, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15200120

ABSTRACT

OBJECT: The purpose of this study was to evaluate both replication-competent and replication-restricted recombinant vesicular stomatitis virus (VSV) vectors as therapeutic agents for high-grade gliomas by using an organotypic brain tissue slice-glioma coculture system. METHODS: The coculture system involved growing different brain structures together to allow neurons from these tissues to develop synaptic connections similar to those found in vivo. Rat C6 or human U87 glioma cells were then introduced into the culture to evaluate VSV as an oncolytic therapy. The authors found that recombinant wild-type VSV (rVSV-wt) rapidly eliminated C6 glioma cells from the coculture, but also caused significant damage to neurons, as measured by a loss of microtubule-associated protein 2 immunoreactivity and a failure in electrophysiological responses from neurons in the tissue slice. Nonetheless, pretreatment with interferon beta (IFNbeta) virtually eliminated VSV infection in healthy tissues without impeding any oncolytic effects on tumor cells. Despite the protective effects of the IFNbeta pretreatment, the tissue slices still showed signs of cytopathology when exposed to rVSV-wt. In contrast, pretreatment with IFNbeta and inoculation with a replication-restricted vector with its glycoprotein gene deleted (rVSV-deltaG) effectively destroyed rat C6 and human U87 glioma cells in the coculture, without causing detectable damage to the neuronal integrity and electrophysiological properties of the healthy tissue in the culture. CONCLUSIONS: Data in this study provide in vitro proof-of-principle that rVSV-deltaG is an effective oncolytic agent that has minimal toxic side effects to neurons compared with rVSV-wt and therefore should be considered for development as an adjuvant to surgery in the treatment of glioma.


Subject(s)
Brain Neoplasms/therapy , Glioma/therapy , Vesicular stomatitis Indiana virus/genetics , Vesicular stomatitis Indiana virus/pathogenicity , Animals , Brain Neoplasms/pathology , Culture Techniques , Electrophysiology , Glioma/pathology , Humans , Interferon-beta/pharmacology , Neurons , Rats , Synapses , Tumor Cells, Cultured
20.
Oncogene ; 23(20): 3700-7, 2004 Apr 29.
Article in English | MEDLINE | ID: mdl-15116101

ABSTRACT

Myelodysplasia/acute myeloid leukemia (MDS/AML) is characterized by a t(3;5)(q25.1;q34) chromosomal translocation that forms a fusion gene between nucleophosmin (NPM) and MDS/myeloid leukemia factor 1 (MLF1). We identified a novel protein, MLF1-interacting protein (MLF1IP), that specifically associates with MLF1 by yeast two-hybrid analysis and in pulldown assays, and colocalizes with it in both the nuclei and cytoplasm of cells. The MLF1IP gene locus is at chromosome 4q35.1 and is composed of 14 exons spanning 75.8 kb of genomic DNA. The MLF1IP cDNA encodes a 46-kDa protein that contains two bipartite and two classical nuclear localization signals, two nuclear receptor-binding motifs (LXXLL), two leucine zippers, two PEST residues and several potential phosphorylation sites. MLF1IP transcripts are expressed in a variety of tissues (e.g. fetal liver, bone marrow, thymus and testis). MLF1IP appears to be a lineage-specific gene whose expression is confined exclusively to the CFU-E erythroid precursor cells, but not in mature erythrocytes. These observations, together with previous data demonstrating a role for MLF1 in suppressing red cell maturation, suggest a possible role for MLF1IP and MLF1 deregulation in the genesis of erythroleukemias.


Subject(s)
Nuclear Proteins/genetics , Proteins/metabolism , Amino Acid Sequence , Base Sequence , Blotting, Northern , Cell Cycle Proteins , DNA, Complementary , DNA-Binding Proteins , Fluorescent Antibody Technique , Hematopoietic Stem Cells/metabolism , Histones , Humans , Molecular Sequence Data , Nuclear Proteins/metabolism , Organ Specificity , Polymerase Chain Reaction , Two-Hybrid System Techniques
SELECTION OF CITATIONS
SEARCH DETAIL
...